Skip to main content
. Author manuscript; available in PMC: 2020 Oct 23.
Published in final edited form as: Cell Rep. 2020 Oct 6;33(1):108226. doi: 10.1016/j.celrep.2020.108226

Figure 7. The Neutralization Activity of Human Vaccine-Elicited Antibody Responses following Cross-Reactive Antibody Depletion against DENV2 Genotypic Variants.

Figure 7.

(A) The neutralization activity of BSA-depleted DENV2-specific IgG neutralizing antibodies from experimentally infected individuals.

(B) The neutralization activity of cross-reactive antibody-depleted DENV2-specific IgG neutralizing antibodies in experimentally infected individuals.

(C) Percent DENV2-serotype-specific neutralizing antibodies in experimentally infected individuals following cross-reactive antibody depletion. Bars denote mean and standard deviation.

See also Table S4.